Viewpoint Molecular Targeting sets sights on growth in 2021

March 8, 2021

Viewpoint Molecular Targeting, an Iowa JPEC Faculty Innovators alumnus, is starting 2021 with momentum. Over the last 6 months, the company accrued $18 million in funding, secured its own supply chain of radioisotopes, unveiled positive preclinical data; and secured its first investigational new drug application by the US FDA in the lead up to their first human trials at the Mayo Clinic and the University of Iowa.

Viewpoint Molecular Recieves $2M in SBIR Funding

October 17, 2017

Viewpoint Molecular Targeting LLC., based at the UI BioVentues Center in Coralville, was awarded a PHase II Small Business Innovation Reserach (SBIR) contract.

Viewpoint Molecular Targeting, LLC, Coralville

January 2, 2018

Mike Schultz and Frances Johnson are looking to bring the number of metastatic melanoma patients down. Based on discoveries in the lab, the duo started Viewpoint Molecular Targeting, LLC, a company based around a revolutionary radio-pharmaceutical to improve those odds.

Viewpoint Wins Iowa SBIR Showcase Phase II Pitch Competition

September 18, 2017

Viewpoint Molecular Targeting LLC, a UIowa Startup that develops therapies and diagnostics for metastatic melanoma, recently placed first at the Iowa SBIR Showcase pitch competition, receiving a prize of $10,000.